-
FDA Advisory Panel Narrowly Endorses Several Peptides Linked to RFK Jr.’s Health Agenda
An FDA advisory committee voted narrowly in favor of several peptide compounds that have drawn public attention from Health and Human Services Secretary Robert F. Kennedy Jr., though the panel’s recommendation is nonbinding and final approval decisions remain with the agency.
-
HHS Signals Shift Toward Easing Restrictions on Psychedelic Research
Reporting indicates that Health and Human Services Secretary Robert F. Kennedy Jr. is following through on pledges to reduce regulatory barriers that have long limited research into psychedelic compounds. The developments could reshape how these substances are studied and potentially used in clinical settings.
-
Experimental Peptide Shows Early Promise in Spinal Cord Nerve Repair Trial
A peptide-based therapy being tested in a clinical trial has reportedly shown signs of nerve repair in patients with spinal cord injuries, according to a recent industry report. Researchers caution that results remain early-stage and require further validation.
-
FDA Advisory Panel Signals Support for Wider Legal Access to Popular Peptides
An FDA advisory committee has recommended expanding legitimate access to several peptide compounds that have circulated widely in unregulated online markets, potentially reshaping how these substances reach consumers.
-
FDA Advisory Panel Backs Wider Access to Six Popular Peptides
An FDA advisory panel has recommended loosening restrictions on six of seven widely discussed peptides, a move that could reshape how these compounds are regulated and accessed in the United States.
-
FDA Advisory Panel Narrowly Backs Adding Six Peptides to Compounding List
An FDA advisory committee voted by a narrow margin to recommend adding six peptide substances to a list eligible for pharmacy compounding, setting up further agency review before any final decision.
-
Report Projects Continued Growth for Global Peptide Therapeutics Market Through 2035
A new market research report forecasts sustained expansion of the global peptide therapeutics industry over the next decade, pointing to rising research investment and drug development activity. The projection reflects broader trends in the sector rather than a specific scientific breakthrough.
-
FDA Advisory Panel Signals Support for Certain Peptides Amid Lingering Safety Questions
A US federal advisory panel has expressed support for continued access to a group of popular peptide compounds, even as regulators and scientists flag unresolved questions about their long-term safety.
-
Advisory Panel Recommends Easing Access to Widely Used Peptide Compound, Even as Safety Questions Linger
A U.S. advisory panel has voted to relax restrictions on a peptide popular in wellness and recovery circles, even though members flagged unresolved safety concerns. The recommendation now heads to federal regulators for further review.
-
Early-Stage Trial Suggests Personalized Vaccine May Help Fight Pancreatic Cancer
A Phase 1 clinical trial has reported encouraging early results for an experimental vaccine designed to help the immune system target pancreatic cancer cells. Researchers say the findings warrant further study in larger trials.